Eating Disorders Occur Across All Age, Ethnic and Gender Groups

MedicalResearch.com Interview with:

Tomoko Udo, PhD Assistant Professor Department of Health Policy, Management, and Behavior School of Public Health University at Albany, State University of New York

Dr. Tomoko Udo

Tomoko Udo, PhD
Assistant Professor
Department of Health Policy, Management, and Behavior
School of Public Health
University at Albany, State University of New York

MedicalResearch.com: What is the background for this study?  

Response: The National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC III) was the largest epidemiological study on psychiatric disorders in US non-institutionalized adults that was conducted by the National Institution on Alcohol Abuse and Alcoholism, and the first one sinceDSM-5 came out. The last population-based study with US adults that examined eating disorders was the National Comorbidity Survey-Replication Study conducted by Hudson and his colleagues and published in 2007.

We felt that it was important to obtain new prevalence estimates in a larger and representative sample especially because the DSM-5 included several changes to the criteria for eating disorders from the earlier DSM-IV. Thus, we thought it was important to provide updated and new prevalence estimates for eating disorders as well as how they are distributed across sex, ethnicity/race, and age.  Many  researchers and clinicians expected higher estimates than earlier studies as a result of “loosening” of diagnostic criteria for eating disorders.

Continue reading

Vyvanse Approved For Moderate To Severe Binge Eating Disorder

MedicalResearch.com Interview with:

Dr. Susan L. McElroy, M.D.</strong> Professor of Psychiatry and Behavioral Neuroscience Chief Research Officer Lindner Center of HOPE University of Cincinnati College of Medicine.

Dr. Susan L. McElroy

Dr. Susan L. McElroy, M.D.
Professor of Psychiatry and Behavioral Neuroscience
Chief Research Officer
Lindner Center of HOPE
University of Cincinnati College of Medicine.

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: SPD489-346, designed as a multi-center, double-blind, placebo-controlled, dose-optimized, randomized-withdrawal study, is the first-ever longer-term pharmacologic study (38 weeks) to evaluate the maintenance of efficacy between Vyvanse and placebo in adults with moderate to severe binge eating disorder (B.E.D.).

Study SPD489-346 evaluated the longer-term maintenance of efficacy (38 weeks) between Vyvanse and placebo based on the primary endpoint of time to relapse during the randomized-withdrawal phase in adults aged 18 to 55 (N=267) with moderate to severe B.E.D. based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition – Text Revision (DSM-IV-TR®) criteria. In the study, relapse was defined as having two or more binge days per week for two consecutive weeks prior to any visit and an increase in Clinical Global Impressions-Severity (CGI-S) score of two or more points relative to the randomized-withdrawal baseline visit

Results from SPD489-346 indicated that Vyvanse (n=136) demonstrated significant maintenance of efficacy compared to placebo (n=131) based upon the primary endpoint of time to relapse. At the conclusion of the study, maintenance of efficacy for patients who had an initial response during the open-label phase, and then continued on Vyvanse during the randomized-withdrawal phase, was demonstrated with Vyvanse being superior over placebo as measured by time to relapse.

Safety and tolerability evaluations of Vyvanse included treatment-emergent adverse events (TEAEs) and vital signs. The safety profile for Vyvanse in this study was generally consistent with the known profile reported in previous studies in adult patients with moderate to severe B.E.D.

Vyvanse is indicated for the treatment of moderate to severe B.E.D. in adults. Vyvanse is not for weight loss. It is not known if Vyvanse is safe and effective for the treatment of obesity.

Vyvanse is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep in a safe place to prevent misuse and abuse. Selling or sharing Vyvanse may harm others and is illegal.

Continue reading

Binge Eating May Predispose to Diabetes

Alison E. Field, ScD Associate Professor of Pediatrics Boston Children's Hospital Division of Adolescent Medicine Boston, MA  02115MedicalResearch.com Interview with:
Alison E. Field, ScD
Associate Professor of Pediatrics Boston Children’s Hospital
Division of Adolescent Medicine
Boston, MA  02115


MedicalResearch.com: What are the main findings of the study?


Answer: Girls who engage in frequent binge eating are much more likely than their peers with the same BMI to develop diabetes. The risk was greatest among girls with binge eating disorder.
Continue reading